The Centers for Medicare & Medicaid Services late today released guidance on how it will implement its August interim final rule that makes collecting and reporting COVID-19 data a condition of participation for hospitals that participate in Medicare. The guidance includes new reporting requirements for hospitals, as well as enforcement provisions. Highlights of the guidance include:

  • the reduction of mandatory supply-related data reports to once-per-week submissions;
  • a requirement that psychiatric and rehabilitation hospitals report data only once per week;
  • beginning on Nov. 1, Remdesivir- and staffing-related data will be optional; and
  • additional reporting requirements that begin Nov. 1 for certain data on influenza patients.

CMS also describes the enforcement process, which will include initial letters notifying non-compliant hospitals. The initial letters for non-compliance will start going out tomorrow and be followed by warning letters beginning three weeks after initial notifications.

Hospitals that remain noncompliant will then receive a letter letting them know they will be terminated from the Medicare program unless they come into compliance within 30 days.

Related News Articles

Headline
The AHA Oct. 3 responded to the Medicare Payment Advisory Commission’s recent analysis on the financial impacts of Medicare Advantage enrollment growth on…
Headline
The Centers for Disease Control and Prevention will update its immunization schedules for the COVID-19 and chickenpox vaccines to adopt recent recommendations…
Headline
The federal government shutdown will continue as the Senate Oct. 3 failed to adopt a government funding deal. The latest attempt to pass the House-passed…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 issued a memo, through the Health Plan Management system, finalizing the Medicare Advantage…
Headline
The federal government shut down Oct. 1 following a failed Senate vote on the House-passed continuing resolution to fund the government by midnight Sept. 30.…
Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…